"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to CCCC. [ FAQ on what and how to ask] For non-CCCC questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Mr. Andrew J. Hirsch M.B.A.
Headquarter: 490 Arsenal Way, Suite120, Watertown, MA, United States, 02472
Industry: Biotechnology, Investment Track: -, Employees: 104
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
My Watchlist
